Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Pain Treatment

Artelo Biosciences announced positive results from its first-in-human Phase 1 study of ART26.12, a novel, orally administered FABP5 inhibitor for pers...
Home/KnloSights/Clinical Trial Updates/Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Pain Treatment